- Home
- TRNO vs BLCO Comparison
TRNO vs BLCO Comparison
Compare TRNO & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNO
- BLCO
- Stock Information
- Founded
- TRNO 2009
- BLCO 1853
- Country
- TRNO United States
- BLCO Canada
- Employees
- TRNO N/A
- BLCO N/A
- Industry
- TRNO Real Estate
- BLCO Ophthalmic Goods
- Sector
- TRNO Finance
- BLCO Health Care
- Exchange
- TRNO Nasdaq
- BLCO Nasdaq
- Market Cap
- TRNO 6.0B
- BLCO 5.2B
- IPO Year
- TRNO 2010
- BLCO 2022
- Fundamental
- Price
- TRNO $57.16
- BLCO $15.21
- Analyst Decision
- TRNO Buy
- BLCO Hold
- Analyst Count
- TRNO 10
- BLCO 12
- Target Price
- TRNO $65.00
- BLCO $15.91
- AVG Volume (30 Days)
- TRNO 630.8K
- BLCO 576.5K
- Earning Date
- TRNO 11-05-2025
- BLCO 10-29-2025
- Dividend Yield
- TRNO 3.65%
- BLCO N/A
- EPS Growth
- TRNO 40.84
- BLCO N/A
- EPS
- TRNO 2.52
- BLCO N/A
- Revenue
- TRNO $425,998,000.00
- BLCO $4,891,000,000.00
- Revenue This Year
- TRNO $21.62
- BLCO $8.29
- Revenue Next Year
- TRNO $10.89
- BLCO $5.82
- P/E Ratio
- TRNO $22.62
- BLCO N/A
- Revenue Growth
- TRNO 22.17
- BLCO 8.81
- 52 Week Low
- TRNO $48.18
- BLCO $10.45
- 52 Week High
- TRNO $69.20
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- TRNO 48.49
- BLCO 56.94
- Support Level
- TRNO $55.94
- BLCO $13.77
- Resistance Level
- TRNO $58.38
- BLCO $15.25
- Average True Range (ATR)
- TRNO 1.02
- BLCO 0.49
- MACD
- TRNO -0.16
- BLCO -0.02
- Stochastic Oscillator
- TRNO 39.71
- BLCO 94.75
About TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.